Stock 300267 HUNAN ER-KANG PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hunan Er-Kang Pharmaceutical Co., Ltd

Equities

300267

CNE100001781

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
2.57 CNY +1.18% Intraday chart for Hunan Er-Kang Pharmaceutical Co., Ltd +8.90% -19.94%
Apr. 26 Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 7,962 10,643 8,684 9,777 7,322 6,621
Enterprise Value (EV) 1 6,504 9,273 7,858 9,267 6,847 6,222
P/E ratio 36.8 x 65.9 x 43 x -12.4 x 160 x -33.9 x
Yield 0.26% 0.19% 1.19% - 0.85% -
Capitalization / Revenue 3.38 x 3.88 x 3.65 x 4.37 x 3.91 x 3.71 x
EV / Revenue 2.76 x 3.38 x 3.3 x 4.15 x 3.66 x 3.49 x
EV / EBITDA 14.8 x 31.8 x 29.6 x 231 x 43.7 x 53.8 x
EV / FCF -241 x 136 x -19.5 x -150 x 190 x 75.8 x
FCF Yield -0.41% 0.73% -5.12% -0.67% 0.53% 1.32%
Price to Book 1.42 x 1.85 x 1.51 x 2.02 x 1.45 x 1.36 x
Nbr of stocks (in thousands) 2,062,605 2,062,605 2,062,605 2,062,605 2,062,605 2,062,605
Reference price 2 3.860 5.160 4.210 4.740 3.550 3.210
Announcement Date 4/24/19 4/24/20 4/27/21 4/27/22 4/26/23 4/24/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,354 2,744 2,382 2,235 1,871 1,783
EBITDA 1 440 291.5 265.9 40.09 156.7 115.6
EBIT 1 309.6 137.7 81.92 -150.5 -10.65 -83.71
Operating Margin 13.15% 5.02% 3.44% -6.73% -0.57% -4.69%
Earnings before Tax (EBT) 1 269.6 175.4 211.7 -845.8 17.35 -198.9
Net income 1 216.6 161.5 202.2 -791.2 45.76 -195.3
Net margin 9.2% 5.89% 8.49% -35.4% 2.45% -10.95%
EPS 2 0.1050 0.0783 0.0980 -0.3836 0.0222 -0.0947
Free Cash Flow 1 -26.99 67.98 -402.6 -61.85 36.11 82.04
FCF margin -1.15% 2.48% -16.9% -2.77% 1.93% 4.6%
FCF Conversion (EBITDA) - 23.32% - - 23.04% 70.99%
FCF Conversion (Net income) - 42.09% - - 78.92% -
Dividend per Share 2 0.0100 0.0100 0.0500 - 0.0300 -
Announcement Date 4/24/19 4/24/20 4/27/21 4/27/22 4/26/23 4/24/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1
Net sales -
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 22.53
Net margin -
EPS 2 0.0109
Dividend per Share -
Announcement Date 4/28/22
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,458 1,370 825 510 475 399
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -27 68 -403 -61.8 36.1 82
ROE (net income / shareholders' equity) 3.81% 2.71% 3.28% -14.9% 0.74% -4.5%
ROA (Net income/ Total Assets) 3.29% 1.41% 0.8% -1.56% -0.12% -0.92%
Assets 1 6,587 11,445 25,212 50,845 -38,811 21,159
Book Value Per Share 2 2.710 2.790 2.800 2.350 2.450 2.360
Cash Flow per Share 2 0.7100 0.6400 0.4300 0.3700 0.3700 0.3600
Capex 1 96.7 364 606 349 173 238
Capex / Sales 4.11% 13.27% 25.43% 15.63% 9.27% 13.36%
Announcement Date 4/24/19 4/24/20 4/27/21 4/27/22 4/26/23 4/24/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD Stock Hunan Er-Kang Pharmaceutical Co., Ltd
-19.94% 732M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 326B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 236B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300267 Stock
  4. Financials Hunan Er-Kang Pharmaceutical Co., Ltd